Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | CYCN | Common Stock | 50.3K | Dec 1, 2023 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | This Amendment to Form 3 increases by 303 shares, the total shares of common stock held by Ms. Graul, reflecting her ownership of these additional shares prior to her becoming President of Cyclerion Therapeutics, Inc. on December 1, 2023. |
F2 | As previously reported, the Reporting Person was granted 50,000 shares of restricted stock on December 1, 2023 pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 10,000 of the shares vested immediately and the remaining 40,000 shares are subject to vesting ratably over a 48-month period, provided that the Reporting Person remains employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. |